In this study, we have further validated the potential therapeutic value of this packaging mechanism, RBMX silencing efficiently prevented BCC-elicited DOXIC aggravating effects by blocking the adverse communication between breast cancer cells and cardiomyocytes. This evidence concerns the gene RBMX and breast cancer.